Literature DB >> 33678168

Hypertension is associated with osteoporosis: a case-control study in Chinese postmenopausal women.

Hao Chai1, Jirong Ge2, Li Li1, Jianyang Li1, Yunjin Ye3.   

Abstract

BACKGROUND: Osteoporosis and cardiovascular disease (CVD) are age-related diseases. It is reported that patients with CVD have a higher risk of bone loss. This retrospective study sought to reveal the association between osteoporosis and CVD in Chinese women. Although epidemiological evidence has indicated a relationship between the two, clinical data in southeast China are lacking.
METHODS: In total, 2873 participants completed the baseline survey from January 2007 to October 2019, and 2039 were included in this retrospective study. We divided all subjects into an osteoporosis group and a non-osteoporosis group based on their bone mineral density (BMD). Dual-energy X-ray absorptiometry (DXA) was used to examine BMD. The general information came from the questionnaire survey. Cardiovascular diseases were defined by asking participants at the first visit and checking relevant medical records if they had suffered from hypertension, coronary heart disease, or cerebral infarction.
RESULTS: According to the criterion, the osteoporosis group had 678 subjects, and the non-osteoporosis group had 1361 subjects. Subjects in the osteoporosis group had a significantly higher prevalence of hypertension and coronary heart disease. Besides, the proportion of subjects who drank tea and drank milk were relatively higher in the osteoporosis group. The odds ratio (OR) for suffering from osteoporosis was high if the patients had hypertension.
CONCLUSIONS: This study indicated that Chinese postmenopausal women with osteoporosis had a higher prevalence of hypertension. Hypertension was significantly associated with osteoporosis.

Entities:  

Keywords:  Association; Bone mineral density; Cardiovascular disease; Hypertension; Osteoporosis

Mesh:

Year:  2021        PMID: 33678168      PMCID: PMC7938480          DOI: 10.1186/s12891-021-04124-9

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  45 in total

Review 1.  The protective effects of estrogen on the cardiovascular system.

Authors:  M E Mendelsohn; R H Karas
Journal:  N Engl J Med       Date:  1999-06-10       Impact factor: 91.245

Review 2.  Changes in proinflammatory cytokine activity after menopause.

Authors:  Johannes Pfeilschifter; Roland Köditz; Martin Pfohl; Helmut Schatz
Journal:  Endocr Rev       Date:  2002-02       Impact factor: 19.871

3.  [Guideline for diagnosis and treatment of patients with chronic stable angina (no abstract)].

Authors: 
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2007-03

4.  Clinical and subclinical cardiovascular disease in female SLE patients: Interplay between body mass index and bone mineral density.

Authors:  J Rodríguez-Carrio; A Martínez-Zapico; I Cabezas-Rodríguez; L Benavente; Á I Pérez-Álvarez; P López; J B Cannata-Andía; M Naves-Díaz; A Suárez
Journal:  Nutr Metab Cardiovasc Dis       Date:  2018-10-15       Impact factor: 4.222

Review 5.  Multifaceted interaction of bone, muscle, lifestyle interventions and metabolic and cardiovascular disease: role of osteocalcin.

Authors:  I Levinger; T C Brennan-Speranza; A Zulli; L Parker; X Lin; J R Lewis; B B Yeap
Journal:  Osteoporos Int       Date:  2017-03-13       Impact factor: 4.507

Review 6.  Estrogen and bone health in men and women.

Authors:  Jane A Cauley
Journal:  Steroids       Date:  2014-12-30       Impact factor: 2.668

7.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.

Authors:  Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick
Journal:  Circulation       Date:  2006-03-14       Impact factor: 29.690

Review 8.  Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

Authors:  Lorenz C Hofbauer; Michael Schoppet
Journal:  JAMA       Date:  2004-07-28       Impact factor: 56.272

Review 9.  Cardiovascular disease and osteoporosis.

Authors:  V Baldini; M Mastropasqua; C M Francucci; E D'Erasmo
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

Review 10.  Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population.

Authors:  Adrian Covic; Marc Vervloet; Ziad A Massy; Pablo Ureña Torres; David Goldsmith; Vincent Brandenburg; Sandro Mazzaferro; Pieter Evenepoel; Jordi Bover; Mugurel Apetrii; Mario Cozzolino
Journal:  Lancet Diabetes Endocrinol       Date:  2017-10-16       Impact factor: 32.069

View more
  4 in total

1.  FGFRL1 and FGF genes are associated with height, hypertension, and osteoporosis.

Authors:  Hye-Won Cho; Hyun-Seok Jin; Yong-Bin Eom
Journal:  PLoS One       Date:  2022-08-18       Impact factor: 3.752

2.  Prevalence of Hypertension and Its Associated Risk Factors Among Patients with Rheumatoid Arthritis in the Kingdom of Saudi Arabia.

Authors:  Abdullah K Al-Ahmari
Journal:  Int J Gen Med       Date:  2022-08-08

3.  Analysis of the prevalence, risk factors, and clinical characteristics of osteoporosis in patients with essential hypertension.

Authors:  Hai-Long Wu; Jie Yang; Yu-Chi Wei; Jian-Yu Wang; Yu-Yan Jia; Luan Li; Lu Zhang; Yan Lu; Zong-Jian Luo; Xiang-Yang Leng
Journal:  BMC Endocr Disord       Date:  2022-06-27       Impact factor: 3.263

4.  The associations between bone mineral density and long-term risks of cardiovascular disease, cancer, and all-cause mortality.

Authors:  Lin Shi; Xiao Yu; Qingjiang Pang; Xianjun Chen; Chenghao Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.